Menopausal Symptoms Cooled By KaNDy's Dual Neurokinin Antagonist
Executive Summary
Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.
You may also be interested in...
Investors Sweet On KaNDy Menopause Treatment
Armed with a fresh injection of £25m, the UK's KaNDy is about to begin Phase IIb trials of a dual mechanism therapy it believes will be a transformational treatment to tackle two key symptoms of the menopause, hot flashes and night time awakenings.
True Innovation In Women’s Health Hindered Because Conditions Are Not Fatal
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
Astellas Culls Positions Ahead Of Big Expiry
Astellas is looking to cut hundreds of positions in Japan as it faces a major upcoming patent expiry and refocuses under a new strategic plan.